Core Viewpoint - The company, Wantai Biological Pharmacy Enterprise Co., Ltd., has successfully bid for the national immunization program's procurement project for the bivalent human papillomavirus (HPV) vaccine, which is expected to enhance its market presence and contribute to cervical cancer elimination efforts in China [1][2]. Group 1: Vaccine Procurement and Market Impact - The company's bivalent HPV vaccine (E. coli) has been included in the national procurement project with a unit price of 27.5 yuan [1]. - The inclusion of the vaccine is anticipated to increase the vaccination rate in China and support the country's goal of eliminating cervical cancer [1]. - The company acknowledges that the domestic market for bivalent HPV vaccines is under pressure due to the availability of imported nine-valent HPV vaccines and changing consumer preferences [2]. Group 2: Recent Developments and Financial Performance - The company has received acceptance for its clinical trial application for a recombinant respiratory syncytial virus vaccine, marking a significant step in its vaccine development strategy [2]. - For the first three quarters of the year, the company reported revenue of 1.498 billion yuan, a year-on-year decrease of 23.09%, and a net loss of 173 million yuan [3]. - In the third quarter, the company achieved revenue of 655 million yuan, reflecting a year-on-year growth of 12.5%, but still reported a net loss of approximately 29.38 million yuan [3].

智通财经APP讯，万泰生物(603392.SH)公告，公司全资子公司厦门万泰沧海生物技术有限公司收到国 家药品监督管理局(简称"国家药监局")行政许可文书《受理通知书》，公司申报的"重组呼吸道合胞病毒 疫苗(CHO细胞)"临床试验申请已获得受理。 ...

人民财讯10月23日电，据成都商报，10月22日，成都迈科康生物科技有限公司(简称"迈科康生物")宣 布，其全资子公司自主研发的重组呼吸道合胞病毒疫苗(CHO细胞)III期临床试验在湖北省咸宁市咸安区 完成首批受试者入组，这是首个获得国家CDE批准临床试验的重组蛋白技术路线国产呼吸道合胞病毒疫 苗。 ...